Oryzon Genomics Past Earnings Performance
Past criteria checks 0/6
Oryzon Genomics's earnings have been declining at an average annual rate of -8.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-8.4%
Earnings growth rate
-0.4%
EPS growth rate
Biotechs Industry Growth | -7.2% |
Revenue growth rate | 6.5% |
Return on equity | -4.3% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch
Jun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?
Apr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts
Jul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?
May 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?
Feb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns
Jan 04Revenue & Expenses BreakdownBeta
How Oryzon Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -4 | 4 | 17 |
30 Sep 23 | 17 | -4 | 3 | 0 |
30 Jun 23 | 17 | -4 | 4 | 0 |
31 Mar 23 | 17 | -5 | 4 | 0 |
31 Dec 22 | 17 | -5 | 4 | 0 |
30 Sep 22 | 10 | -3 | 4 | 1 |
30 Jun 22 | 14 | -5 | 3 | 0 |
31 Mar 22 | 12 | -5 | 4 | 0 |
31 Dec 21 | 12 | -5 | 4 | 0 |
30 Sep 21 | 11 | -4 | 5 | 1 |
30 Jun 21 | 10 | -4 | 5 | 0 |
31 Mar 21 | 7 | -5 | 5 | 4 |
31 Dec 20 | 12 | -4 | 5 | 0 |
30 Sep 20 | 12 | -4 | 4 | 0 |
30 Jun 20 | 13 | -4 | 4 | 0 |
31 Mar 20 | 13 | -4 | 4 | 0 |
31 Dec 19 | 12 | -4 | 4 | 0 |
30 Sep 19 | 10 | -4 | 4 | 0 |
30 Jun 19 | 9 | -4 | 4 | 0 |
31 Mar 19 | 8 | -2 | 3 | 0 |
31 Dec 18 | 8 | -1 | 4 | 0 |
30 Sep 18 | 7 | -2 | 4 | 0 |
30 Jun 18 | 6 | -2 | 4 | 0 |
31 Mar 18 | 6 | -6 | 4 | 0 |
31 Dec 17 | 5 | -6 | 4 | 0 |
30 Sep 17 | 6 | -6 | 4 | 0 |
30 Jun 17 | 6 | -6 | 3 | 0 |
31 Mar 17 | 5 | -6 | 3 | 0 |
31 Dec 16 | 5 | -6 | 3 | 0 |
30 Sep 16 | 6 | -5 | 3 | 0 |
30 Jun 16 | 6 | -4 | 2 | 0 |
31 Mar 16 | 8 | -1 | 3 | 0 |
31 Dec 15 | 8 | -1 | 2 | 0 |
30 Sep 15 | 8 | -1 | 2 | 0 |
30 Jun 15 | 7 | -1 | 2 | 0 |
31 Mar 15 | 11 | 2 | 2 | 0 |
31 Dec 14 | 19 | 8 | 2 | 0 |
31 Dec 13 | 3 | -3 | 2 | 0 |
Quality Earnings: ORY is currently unprofitable.
Growing Profit Margin: ORY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORY is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare ORY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: ORY has a negative Return on Equity (-4.32%), as it is currently unprofitable.